Non-small Cell Lung Cancer
Conditions
Brief summary
To better understand your feelings and expectations about immunotherapy
Detailed description
Primary Objective: 1\. To compare expectations of survival benefit from immunotherapy between advanced cancer patients with poor performance status (PS) and their oncologists. We hypothesize that, compared to their oncologists, patients will have expectations for greater likelihood of survival beyond 2 years. Secondary Objectives: 1. To compare expectations of therapeutic benefit of immunotherapy between advanced cancer patients with poor PS and their oncologists. We hypothesize that, compared to their oncologists, patients will have expectations for greater likelihood of cure, quality of life improvement, and lower likelihood of adverse events. 2. To qualitatively describe the priorities and preferences for information of advanced cancer patients with poor PS when considering immunotherapy treatment. 3. To evaluate the associations between discrepant expectations with patients' sociodemographic and clinical characteristics. 4. To compare patient and oncologist expectations with actual treatment outcomes and survival.
Interventions
BEHAVIORALQuestionnaires
Participants will complete 5 questionnaires about any symptoms participants may be having, any anxiety and/or depression participants may be having, your preference in decision-making, and your expectations about your treatment. It should take about 30 minutes to complete all 5 questionnaires
BEHAVIORALInterview
The interview will last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom or FaceTime (based on your preference)
Sponsors
Conquer Cancer Foundation
M.D. Anderson Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients being considered for or within 2 months of starting immunotherapy for advanced cancer 2. Patient ≥18 years of age 3. ECOG ≥2 4. Cognitively able to understand consent and complete questionnaire as determined by the interviewer at the time of study enrollment 5. English speaking 6. Willing to participate in the study and sign informed consent 7. The study will include medical oncologists that treat advanced cancers
Exclusion criteria
1. Treatment for curative intent 2. Presence of Delirium (as determined by score \>13 on MDAS 46, appendix A)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Discrepancy in expectation of survival for 2 years or more between the patient and oncologist | through study completion; an average of 2 years |
Countries
United States
Outcome results
None listed